Physician profile
Janene E Jarrett
NPI 1396702544
$3,652.75
in general payments reported to CMS, 2019-2025
29 companies · $684 in 2025
The $684 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $718 · 2022: $754 · 2023: $510 · 2024: $987 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $468.95 | 2022-2024 | Benlysta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $437.36 | 2024-2025 | Xifaxan |
| Janssen Biotech, INC. | $412.43 | 2021-2024 | Tremfya, Simponi Aria |
| Amgen INC. | $388.83 | 2024-2025 | Krystexxa, Uplizna, Tepezza |
| Takeda Pharmaceuticals U.S.A., INC. | $253.80 | 2022-2023 | Entyvio |
| Astrazeneca Pharmaceuticals LP | $243.86 | 2021-2025 | Saphnelo |
| Abbvie INC. | $209.54 | 2021-2024 | |
| Ucb, INC. | $196.95 | 2022-2024 | Cimzia |
| Coloplast Corp | $149.33 | 2021 | |
| Ardelyx, INC. | $132.41 | 2023-2025 | Ibsrela |
| Astellas Pharma US INC | $98.99 | 2021 | |
| Gilead Sciences, INC. | $82.69 | 2022-2025 | |
| Boston Scientific Corporation | $74.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $70.54 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $67.45 | 2024 | Idacio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $48.77 | 2021 | |
| Ironwood Pharmaceuticals, INC | $41.62 | 2022 | |
| Lilly USA, LLC | $33.60 | 2023 | Taltz |
| Urogen Pharma, INC. | $32.30 | 2021 | |
| Genentech USA, INC. | $29.00 | 2025 | Gazyva |
| Allergan, INC. | $28.42 | 2021 | |
| Intercept Pharmaceuticals, INC. | $25.06 | 2023 | Ocaliva |
| Bioventus LLC | $24.72 | 2022 | |
| Novo Nordisk INC | $22.63 | 2023 | |
| Nestle Healthcare Nutrition INC. | $19.15 | 2022 | |
| Viiv Healthcare Company | $18.93 | 2022 | |
| Dendreon Pharmaceuticals LLC | $18.03 | 2021 | |
| Merck Sharp & Dohme LLC | $15.84 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.91 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janene Jarrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.